… impact of obesity on this compound. This includes data obtained from both healthy obese
volunteers and obese patients with various CVD conditions enrolled in rivaroxaban clinical …

… of rivaroxaban versus warfarin in obese patients with venous … safety of rivaroxaban versus
warfarin in obese VTE patients. … Patients with a body mass index (BMI) ≥ 30 kg/m 2 admitted …

… safety of rivaroxaban and warfarin among younger patient … of the DOAC rivaroxaban is not
altered in patients with high … benefits associated with rivaroxaban in obese patientsCitation 23 …

… The results of this study indicate that AF patients with morbid obesity initiating rivaroxaban
… comparable efficacy and safety of rivaroxaban versus warfarin in patients with diverse body …

… Using a large US healthcare claims database, we compared the effectiveness, safety,
healthcare resource utilization, and costs of rivaroxaban and warfarin in morbidly obese patients. …

… morbid obese patients. Thus, the objective of this study was to evaluate the effectiveness …
safety of rivaroxaban compared to warfarin in obese patients with NVAF using patient-level BMI …

… oral anticoagulants (DOACs) in those with a BMI > 40 or weight > 120 kg. The … safety of
apixaban and rivaroxaban, prescribed in morbidly obese patients compared to nonobese patients…

… VTE patients with obesity who received rivaroxaban versus … rivaroxaban is safe and effective
versus warfarin, and associated with lower medical costs among VTE patients with obesity…

… of the 146 obese patients receiving apixaban or rivaroxaban for … Twenty-seven (18%) patients
were from Brest University hospital … BMI ranged from 30.1 to 54 kg/m 2 , with 20% patients …

… ’ hesitancy in prescribing rivaroxaban for overweight/obese patients for the treatment and …
the PK of rivaroxaban in patients with VTE who are obese. Despite the fact that obesity is one …